Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2002.06.020 on July 1 2002

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winer, E. P.
Right arrow Articles by Browman, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winer, E. P.
Right arrow Articles by Browman, G. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 15 (August), 2002: 3317-3327
© 2002 American Society for Clinical Oncology

ASCO SPECIAL ARTICLES

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002

By Eric P. Winer, Clifford Hudis, Harold J. Burstein, Rowan T. Chlebowski, James N. Ingle, Stephen B. Edge, Eleftherios P. Mamounas, Julie Gralow, Lori J. Goldstein, Kathleen I. Pritchard, Susan Braun, Melody A. Cobleigh, Amy S. Langer, Judy Perotti, Trevor J. Powles, Timothy J. Whelan, George P. Browman

From the American Society of Clinical Oncology, Alexandria, VA.

Address reprint requests to American Society of Clinical Oncology, Health Services Research Department, 1900 Duke St, Suite 200, Alexandria, VA 22314; email: guidelines{at}asco.orgThis article was published online ahead of print at www.jco.org.

OBJECTIVE: To conduct an evidence-based technology assessment to determine whether the routine use of anastrozole or any of the aromatase inhibitors in the adjuvant breast cancer setting is appropriate for broad-based conventional use in clinical practice.

POTENTIAL INTERVENTIONS: Anastrozole, letrozole, and exemestane.

OUTCOMES: Outcomes of interest include breast cancer incidence, breast cancer-specific survival, overall survival, and net health benefit.

EVIDENCE: A comprehensive, formal literature review was conducted for relevant topics and is detailed in the text. Testimony was collected from invited experts and interested parties. The American Society of Clinical Oncology (ASCO)–prescribed technology assessment procedure was followed.

BENEFITS/HARMS: The ASCO panel recognizes that a woman and her physician’s decision regarding adjuvant hormonal therapy is complex and will depend on the importance and weight attributed to information regarding both cancer and non–cancer-related risks and benefits.

CONCLUSION: The panel was influenced by the compelling, extensive, and long-term data available on tamoxifen. Overall, the panel considers the results of the Arimidex (anastrozole) or Tamoxifen Alone or in Combination (ATAC) trial and the extensive supporting data to be very promising but insufficient to change the standard practice at this time (May 2002). A 5-year course of adjuvant tamoxifen remains the standard therapy for women with hormone receptor–positive breast cancer. The panel recommends that physicians discuss the available information with patients, and, in making a decision, acknowledge that treatment approaches can change over time. Individual health care providers and their patients will need to come to their own conclusions, with careful consideration of all of the available data. (Specific questions addressed by the panel are summarized in Appendix 3.)

VALIDATION: The conclusions of the panel were endorsed by the ASCO Health Services Research Committee and the ASCO Board of Directors.

SPONSOR: American Society of Clinical Oncology.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
M.F.G. Verberg, N.S. Macklon, G. Nargund, R. Frydman, P. Devroey, F.J. Broekmans, and B.C.J.M. Fauser
Mild ovarian stimulation for IVF
Hum. Reprod. Update, January 1, 2009; 15(1): 13 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. E. Cazzaniga, G. Mustacchi, P. Pronzato, A. De Matteis, F. Di Costanzo, I. Floriani, and On behalf of the NORA Study Group
Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study
Ann. Onc., December 1, 2007; 18(12): 1976 - 1980.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Chen, S.-R. Oh, S. Phung, G. Hur, J. J. Ye, S. L. Kwok, G. E. Shrode, M. Belury, L. S. Adams, and D. Williams
Anti-Aromatase Activity of Phytochemicals in White Button Mushrooms (Agaricus bisporus)
Cancer Res., December 15, 2006; 66(24): 12026 - 12034.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
E. V. McCloskey
Aromatase Inhibitors and Bone Health
IBMS BoneKEy, June 1, 2006; 3(6): 5 - 13.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Kijima, S. Phung, G. Hur, S.-L. Kwok, and S. Chen
Grape Seed Extract Is an Aromatase Inhibitor and a Suppressor of Aromatase Expression
Cancer Res., June 1, 2006; 66(11): 5960 - 5967.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. U. Buzdar and J. Cuzick
Optimum Use of Aromatase Inhibitors in the Adjuvant Treatment of Early Breast Cancer
J. Clin. Oncol., November 20, 2005; 23(33): 8544 - 8546.
[Full Text] [PDF]

Home page
 The OncologistHome page
M. Cianfrocca and W. J. Gradishar
Controversies in the Therapy of Early Stage Breast Cancer
Oncologist, November 1, 2005; 10(10): 766 - 779.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. S. Mann, J. R. Johnson, R. Kelly, R. Sridhara, G. Williams, and R. Pazdur
Letrozole in the Extended Adjuvant Treatment of Postmenopausal Women with History of Early-Stage Breast Cancer Who Have Completed 5 Years of Adjuvant Tamoxifen
Clin. Cancer Res., August 15, 2005; 11(16): 5671 - 5677.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
R. Kudachadkar and R. M. O'Regan
Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer
CA Cancer J Clin, May 1, 2005; 55(3): 145 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. Itoh, K. Karlsberg, I. Kijima, Y.-C. Yuan, D. Smith, J. Ye, and S. Chen
Letrozole-, Anastrozole-, and Tamoxifen-Responsive Genes in MCF-7aro Cells: A Microarray Approach
Mol. Cancer Res., April 1, 2005; 3(4): 203 - 218.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Strasser-Weippl and P. E. Goss
Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
J. Clin. Oncol., March 10, 2005; 23(8): 1751 - 1759.
[Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, C. Hudis, H. J. Burstein, A. C. Wolff, K. I. Pritchard, J. N. Ingle, R. T. Chlebowski, R. Gelber, S. B. Edge, J. Gralow, et al.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004
J. Clin. Oncol., January 20, 2005; 23(3): 619 - 629.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Ingle
Endocrine Therapy Trials of Aromatase Inhibitors for Breast Cancer in the Adjuvant and Prevention Settings
Clin. Cancer Res., January 15, 2005; 11(2): 900s - 905s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. K. Dunn, D. L. Wickerham, and L. G. Ford
Prevention of Hormone-Related Cancers: Breast Cancer
J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Buzdar and C. Macahilig
How Rapidly Do Oncologists Respond to Clinical Trial Data?
Oncologist, January 1, 2005; 10(1): 15 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. S. Tobias
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention
Ann. Onc., December 1, 2004; 15(12): 1738 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
International Breast Cancer Study Group
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93
Ann. Onc., December 1, 2004; 15(12): 1749 - 1759.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Chen, M. Cho, K. Karlsberg, D. Zhou, and Y.-C. Yuan
Biochemical and Biological Characterization of a Novel Anti-aromatase Coumarin Derivative
J. Biol. Chem., November 12, 2004; 279(46): 48071 - 48078.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
K. L Jones and A. U Buzdar
A review of adjuvant hormonal therapy in breast cancer
Endocr. Relat. Cancer, September 1, 2004; 11(3): 391 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N Angelopoulos, V Barbounis, S Livadas, D Kaltsas, and G Tolis
Effects of estrogen deprivation due to breast cancer treatment
Endocr. Relat. Cancer, September 1, 2004; 11(3): 523 - 535.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
ESHRE Capri Workshop Group
Hormones and breast cancer
Hum. Reprod. Update, July 1, 2004; 10(4): 281 - 293.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Cristofanilli and G. N. Hortobagyi
Breast Cancer Highlights: Key Findings from the San Antonio Breast Cancer Symposium: A U.S. Perspective
Oncologist, July 1, 2004; 9(4): 471 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. B. Bouker, T. C. Skaar, D. R. Fernandez, K. A. O'Brien, R. B. Riggins, D. Cao, and R. Clarke
Interferon Regulatory Factor-1 Mediates the Proapoptotic but Not Cell Cycle Arrest Effects of the Steroidal Antiestrogen ICI 182,780 (Faslodex, Fulvestrant)
Cancer Res., June 1, 2004; 64(11): 4030 - 4039.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Kisanga, J. Gjerde, A. Guerrieri-Gonzaga, F. Pigatto, A. Pesci-Feltri, C. Robertson, D. Serrano, G. Pelosi, A. Decensi, and E. A. Lien
Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial
Clin. Cancer Res., April 1, 2004; 10(7): 2336 - 2343.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
T. Shenkier, L. Weir, M. Levine, I. Olivotto, T. Whelan, and L. Reyno
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer
Can. Med. Assoc. J., March 16, 2004; 170(6): 983 - 994.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. U. Buzdar
Data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial: Implications for Use of Aromatase Inhibitors in 2003
Clin. Cancer Res., January 1, 2004; 10(1): 355S - 361S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Ingle
Sequencing of Endocrine Therapy in Postmenopausal Women with Advanced Breast Cancer
Clin. Cancer Res., January 1, 2004; 10(1): 362S - 367S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. E. Goss and K. Strasser-Weippl
Prevention Strategies with Aromatase Inhibitors
Clin. Cancer Res., January 1, 2004; 10(1): 372S - 379S.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. T. Eng, J. Ye, D. Williams, S. Phung, R. E. Moore, M. K. Young, U. Gruntmanis, G. Braunstein, and S. Chen
Suppression of Estrogen Biosynthesis by Procyanidin Dimers in Red Wine and Grape Seeds
Cancer Res., December 1, 2003; 63(23): 8516 - 8522.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. E. Goss, J. N. Ingle, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. Castiglione, D. Tu, L. E. Shepherd, K. I. Pritchard, et al.
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
N. Engl. J. Med., November 6, 2003; 349(19): 1793 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. J. Burstein
Beyond Tamoxifen -- Extending Endocrine Treatment for Early-Stage Breast Cancer
N. Engl. J. Med., November 6, 2003; 349(19): 1857 - 1859.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Osipo, C. Gajdos, H. Liu, B. Chen, and V. C. Jordan
Paradoxical Action of Fulvestrant in Estradiol-Induced Regression of Tamoxifen-Stimulated Breast Cancer
J Natl Cancer Inst, November 5, 2003; 95(21): 1597 - 1608.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, and H.-J. Senn
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
J. Clin. Oncol., September 1, 2003; 21(17): 3357 - 3365.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. U. Buzdar
Advances in Endocrine Treatments for Postmenopausal Women with Metastatic and Early Breast Cancer
Oncologist, August 1, 2003; 8(4): 335 - 341.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
C. E. Holmes and H. B. Muss
Diagnosis and Treatment of Breast Cancer in the Elderly
CA Cancer J Clin, July 1, 2003; 53(4): 227 - 244.
[Abstract] [Full Text]

Home page
 JCOHome page
E. P. Winer, C. Hudis, H. J. Burstein, J. Bryant, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, R. Gelber, J. Gralow, et al.
American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting
J. Clin. Oncol., July 1, 2003; 21(13): 2597 - 2599.
[Full Text] [PDF]

Home page
 NEJMHome page
I. E. Smith and M. Dowsett
Aromatase Inhibitors in Breast Cancer
N. Engl. J. Med., June 12, 2003; 348(24): 2431 - 2442.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. Wu and P. Brown
Is Low-Dose Tamoxifen Useful for the Treatment and Prevention of Breast Cancer?
J Natl Cancer Inst, June 4, 2003; 95(11): 766 - 767.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. Decensi, C. Robertson, G. Viale, F. Pigatto, H. Johansson, E. R. Kisanga, P. Veronesi, R. Torrisi, M. Cazzaniga, S. Mora, et al.
A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers
J Natl Cancer Inst, June 4, 2003; 95(11): 779 - 790.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. L. Riggs and L. C. Hartmann
Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice
N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Brodie, D. Jelovac, and B. J. Long
Predictions from a Preclinical Model: Studies of Aromatase Inhibitors and Antiestrogens
Clin. Cancer Res., January 1, 2003; 9(1): 455S - 459S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Ligibel and E. P. Winer
Clinical Differences among the Aromatase Inhibitors
Clin. Cancer Res., January 1, 2003; 9(1): 473S - 479S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Ingle
Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 480S - 485S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. C. Henderson
A Rose Is No Longer a Rose
J. Clin. Oncol., August 15, 2002; 20(16): 3365 - 3368.
[Full Text] [PDF]

Home page
 JCOHome page
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister
American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online